The Lancet Neurology
Volume 16, No. 6, p413–414, June 2017
Gavin Giovannoni
All neurodegenerative diseases have a preclinical phase during which damage occurs. This phase might be associated with subtle symptoms and signs that do not warrant a diagnosis—ie, a prodrome. Identification of a prodrome is important because it might allow clinicians to diagnose disease earlier. With the emergence of disease-modifying therapies, identification of patients in the preclinical phase of the disease might improve disease outcomes…
